Biogen (NASDAQ: BIIB) today announced new findings detailing the benefits that SPINRAZA® (nusinersen) demonstrates for both infantile- and later-onset spinal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Ionis Pharma (IONS) Highlights Top-Line Data from Phase 1/2 Study of ONIS-HTTRx (RG6042) at AAN MeetingsApril 24, 2018 12:17 PM Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q April 24, 2018 8:48 AM Biogen (BIIB) Tops Q1 EPS by 13c, Miss on RevenuesApril 24, 2018 7:00 AM Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration April 23, 2018 8:14 AM New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for InfantsApril 23, 2018 7:30 AM SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction April 20, 2018 12:05 PM Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug DevelopmentApril 20, 2018 6:37 AM